crohn's

SEW 2871 is an orally available, highly selective S1P1 agonist with an EC50 of 13.8 nM.It reduces the number of lymphocytes in the blood and is used in studies related to diabetes, Alzheimer's disease, liver fibrosis, and inflammation. It activates ERK, Akt and Rac signaling pathways and induces S1P1 internalization and recycling.

Palmatine chloride an isoquinoline alkaloid, is an important medicinal herbal extract with diverse pharmacological and biological properties.

Oxazolone has been used as a haptenizing agent to induce inflammatory responses in intestinal tissue of adult zebrafish and as a model for gene expression studies in two forms of inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Etiprednol dicloacetate (BNP-166) is a corticosteroid with anti-inflammatory activity.Etiprednol dicloacetate inhibits the accumulation of eosinophils and can be used in the study of inflammatory airway diseases such as asthma and in the treatment of Crohn's disease.

5-Acetylsalicylic acid (5-acetyl-2-hydroxybenzoic acid) has anti-inflammatory effects and can be used to treat inflammatory bowel disease, including ulcerative colitis, inflamed anus or rectum, and to maintain remission in Crohn's disease.

1. Palmatine (Burasaine) is an inhibitor of dopamine generation. 2. Palmatine could potentially be developed for the treatment of flavivirus infections. 3. Palmatine has been used in the treatment of jaundice, dysentery, hypertension, inflammation, and liver-related diseases.

Cosyntropin (acetate) stimulates the release of corticosteroids such as cortisol from the adrenal gland.

Sibofimloc (Antibiotic-202), an antibiotic compound, is used in treating bacterial infections.

Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.

Loperamide oxide (R 58425) is a secreted antidiarrheal agent that increases peristalsis and inhibits intestinal absorption of water and ions and is used in the study of chronic diarrhea in patients with Crohn's disease.

Delmitide, a TNF-alpha production inhibitor, is used potentially for the treatment of Crohn's disease and ulcerative colitis.

CP-461 (OSI-461) is a pde2a 5A inhibitor, which may be used in the treatment of renal cell carcinoma, prostate cancer, and Crohn's disease.

Semapimod tetrahydrochloride (CPSI-2364 tetrahydrochloride) is a synthetic ornithine mitogen-activated protein kinase blocker and pro-inflammatory cytokine production inhibitor that interferes with macrophage and microglia function. Sematimod tetrahydrochloride inhibits TLR4 signaling, TNF-α, IL-1β, and IL-6, and is used in the study of Crohn's disease and other inflammatory conditions.

Filgotinib (maleate) is a selective, orally active JAK1 inhibitor that effectively inhibits the activity of JAK1 (IC50: 10 nM), JAK2 (IC50: 28 nM), JAK3 (IC50: 810 nM) and TYK2 (IC50: 116 nM). maleate) can be used to study rheumatoid arthritis (RA) and Crohn's disease.

Omilancor (BT-11) is a direct LANCL2 (Lanthionine Synthetase Cyclase-Like 2) activator with oral activity for the treatment of Crohn's Disease (CD), Inflammatory Bowel Disease (IBD) and Ulcerative Colitis (UC).

Ozanimod (RPC-1063) (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis, and Relapsing Multiple Sclerosis.

Filgotinib hydrochloride hydrate is a potent and selective JAK1 inhibitor under investigation for the treatment of rheumatoid arthritis (RA) and Crohn's disease.

Glepaglutide (ZP1848), a long-acting glucagon-like peptide-2 (GLP-2) analogue, functions as a potent GLP-2 receptor (GLP-2R) agonist, effectively reducing fecal output and enhancing intestinal absorption while alleviating small intestine inflammation. It holds potential for researching inflammatory bowel disease (IBD) and Crohn's disease [1] [2] [3].

Glepaglutide (ZP1848) acetate is a long-acting glucagon-like peptide-2 (GLP-2) analogue and a potent GLP-2 receptor (GLP-2R) agonist. It significantly reduces fecal output and enhances intestinal absorption while also mitigating inflammation in the small intestine. Glepaglutide acetate is relevant in researching inflammatory bowel disease (IBD) and Crohn's disease [1] [2] [3].

Eldelumab (BMS-936557) is a humanized anti-IP-10 IgG type 1 monoclonal antibody with inhibitory activity against CXCL10. It has anti-inflammatory properties, selectively binds to CXCL10, and can be used in the study of rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

Fontolizumab (HuZAF) is a humanized monoclonal antibody targeting IFN-gamma, functioning as an immunosuppressive agent and utilized in the study of Crohn's disease [1].

Visilizumab, a humanized IgG2 monoclonal antibody with low Fc receptor binding affinity, targets the CD3 epsilon (CD3ε) subunit. It is utilized in research related to ulcerative colitis and Crohn's disease [1].

Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohn's disease research.